Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2025-04-28 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
江苏四环生物股份有限公司2024年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as the 2024 annual financial settlement report of Jiangsu Sihuan Bioengineering Co., Ltd. It contains detailed financial data for the year 2024, including income, profit, asset composition, cash flow, revenue, and cost breakdowns. It mentions that the financial statements have been audited by a CPA firm with an unqualified opinion. The document also states that the report has been approved by the board and will be submitted to the shareholders' meeting for approval. The length is 3893 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or certification. This matches the characteristics of an Annual Report (10-K) or a full-year financial report. Given the detailed financial data and audit report inclusion, this is best classified as an Annual Report (10-K). FY 2024
2025-04-28 Chinese
内部控制审计报告
Regulatory Filings
2025-04-28 Chinese
独立董事年度述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2024" from Jiangsu Sihuan Bioengineering Co., Ltd. It details the independent director's background, independence statement, attendance at board and committee meetings, oversight activities, and efforts to protect shareholder interests during the year 2024. The content is a narrative report on the director's duties and activities rather than a financial report or announcement. It does not contain financial statements, earnings data, or regulatory filings. It is a management-related report focusing on board oversight and governance activities by an independent director. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements related to board or senior management activities and reports.
2025-04-28 Chinese
江苏四环生物股份有限公司关于2024年度拟不进行利润分配的专项说明
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a formal announcement from Jiangsu Sihuan Bio about the company's 2024 profit distribution plan, specifically stating that no profit distribution or capital reserve conversion to shares will be made due to negative net profits and accumulated losses. It references the 2024 fiscal year and includes details on net profits, retained earnings, and compliance with relevant regulations. The document is relatively short (2229 characters) and serves as a notice to shareholders about the profit distribution proposal to be submitted to the 2024 Annual General Meeting for approval. It does not contain full financial statements or comprehensive financial analysis, but rather a specific announcement regarding dividend policy and profit distribution plans. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly Notice of Dividend Amount (DIV). However, since it explicitly states the plan to not distribute profits and is a formal announcement related to shareholder voting on profit distribution, it aligns more closely with Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-04-28 Chinese
江苏四环生物股份有限公司关于2024年度计提资产减值准备及核销资产的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Jiangsu Sihuan Bio Co., Ltd. regarding the 2024 annual asset impairment provision and asset write-offs. It details the impairment testing, accounting policies, and the financial impact on the 2024 consolidated financial statements. The document includes specific figures for bad debt provisions, inventory write-downs, intangible asset impairments, and contract asset provisions, as well as explanations of the methods used for impairment testing and credit loss estimation. It also contains opinions from the board audit committee, the board of directors, and the supervisory board, and mentions that the impairment provisions have been audited by an accounting firm. The document is not a full annual report or interim report but a specific announcement about asset impairment provisions and write-offs for the fiscal year 2024. It is a regulatory announcement related to accounting estimates and asset valuation adjustments, not a full financial report or earnings release. Given the detailed nature and the focus on impairment provisions and write-offs, this fits best under Regulatory Filings (RNS) as it is a compliance disclosure about accounting estimates and asset impairment rather than a full audit report or annual report.
2025-04-28 Chinese
江苏四环生物股份有限公司关于子公司被移出失信被执行人名单的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (529 characters) regarding the removal of a subsidiary from a dishonesty enforcement list by a court. It references a previous announcement and provides an update on the status. There are no financial statements, detailed financial data, or comprehensive reports. The document serves as a regulatory update to investors about a legal and compliance matter related to the company and its subsidiary. It fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not qualify as a full report or other specific filing types.
2025-04-17 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.